KYMERA THERAPEUTICS, INC. SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount
KYMERA THERAPEUTICS, INC. (KYMR) had SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount of $120.10 million as of 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Notes
us-gaap:ValuationAllowancesAndReservesBalance · last filed 2023-02-23
- 2022-12-31: SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount $120.10M.
- 2021-12-31: SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount $78.00M.
- 2020-12-31: SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount $34.10M.
- 2019-12-31: SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount $20.90M.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount |
|---|---|
| 2022-12-31 | $120.10M 10-K · filed 2023-02-23 |
| 2021-12-31 | $78.00M 10-K · filed 2023-02-23 |
| 2020-12-31 | $34.10M 10-K · filed 2022-02-24 |
| 2019-12-31 | $20.90M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |